Category: Parkinson's Disease: Non-Motor Symptoms
Objective: The aim of the present study was to identify predictors of non-motor symptoms burden non-progression (NMSB-NP) in PD patients from a Spanish cohort [1,2].
Background: Although it is known that non-motor symptoms (NMS) progress throughout the course of the disease in Parkinson´s disease (PD), some patients can have a better outcome and improve after interventions.
Method: PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed-up during 2 years. The Non-Motor Symptoms Scale (NMSS) was administered at baseline (V0) and at 24 months ± 1 month (V2). NMSB-NP was defined as presenting a score at V2 equal to or less than the baseline (V0) NMSS total score.
Results: Mean NMS burden (NMSS total score) was significantly increased in PD patients (62.6 ± 8.5 years old; 59.4% males; N=501) by by 18.8% (from 45.1 ± 37.6 to 53.6 ± 42.3; p<0.0001). Forty percent of the patients (201/501) were classified as having NMSB-NP at V2. Whereas longer disease duration at V0 (OR 0.902; 95% CI, 0.847-0.961; p=0.001) and a greater increase in BDI-II (Beck Depression Inventory II) total score from V0 to V2 (OR 0.949; 95% CI, 0.919-0.980; p=0.001) were associated with lower probability of NMSB-NP at 2 years follow-up, a higher NMSS total score at V0 (OR 1.019; 95% CI, 1.011-1.026; p<0.0001) and to be taking an antidepressant agent at V2 (OR 1.928; 95% CI, 1.115-3.333; p=0.019) were associated with higher probability, after adjustment to age, gender, change in levodopa, dopamine agonist and levodopa equivalent daily dose, change in motor status (UPDRS [Unified Parkinson´s Disease Rating Scale] part III and IV), exercising regularly, and to be taking levodopa, a dopamine agonist, a MAO-B inhibitor, and a COMT inhibitor.
Conclusion: Receiving antidepressant treatment and less deterioration in mood are independent factors associated with NMS burden non-progression in PD patients after 2 years follow-up.
References: 1. Santos-García D, Mir P, Cubo E, et al.; COPPADIS Study Group. BMC Neurol 2016;16:26. 2. Santos García D, Jesús S, Aguilar M, et al.; COPPADIS Study Group. Eur J Neurol 2019;16:1399-407.
To cite this abstract in AMA style:D. Santos García, C. Cores, T. de Deus, J. Paz González, C. Martínez, E. Suárez, S. Jesús, M. Aguilar, P. Pastor, L. Planellas, M. Cosgaya, J. García Caldentey, N. Caballol, I. Legarda, J. Hernández Vara, I. Cabo, L. López Manzanares, I. González Aramburu, M. Avila, M. Catalán, V. Nogueira, V. Puente, J. García Moreno, C. Borrué, B. Solano, M. álvarez Sauco, L. Vela, S. Escalante, E. Cubo, F. Carrillo, J. Martínez Castrillo, P. Sánchez Alonso, G. Alonso Losada, N. López Ariztegui, I. Gastón, J. Kulisevsky, M. Blázquez, M. Seijo, J. Ruíz Martínez, C. Valero, M. Kurtis, O. de Fábregues, J. González, C. Ordás, L. López Díaz, P. Mir, P. Martínez Martín, C. Coppadis. Mood is a Key Factor in Progression of Non-Motor Symptoms Burden in Parkinson´s disease. [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/mood-is-a-key-factor-in-progression-of-non-motor-symptoms-burden-in-parkinsons-disease/. Accessed December 11, 2023.
« Back to MDS Virtual Congress 2021
MDS Abstracts - https://www.mdsabstracts.org/abstract/mood-is-a-key-factor-in-progression-of-non-motor-symptoms-burden-in-parkinsons-disease/